Centessa Pharmaceuticals’ Post

Read full release here: https://lnkd.in/eA8uYK-C

Centessa’s orexin agonist development team leaders engaged with members of the #sleepdisorders community at SLEEP 2024 Meeting in Houston.  (Pictured: Mario Alberto Accardi PhD, Emmanuel JM Mignot MD PhD, Deborah Hartman, PhD)

Members of Centessa’s orexin agonist development team participated in @Sleep Research Society’s recent Industry Advisory Council round-table discussions at the SLEEP 2024 meeting.   As a proud sponsor of the Sleep Research Society, Centessa was thrilled both to support and contribute to discussions regarding the development of new therapies for those with #sleepdisorders during this event!  

Join Centessa and the idiopathic hypersomnia community in recognizing today as the inaugural Idiopathic Hypersomnia Day (#IHDay). IH is a chronic sleep disorder.   Centessa is proud to sponsor Hypersomnia Foundation, a group who designated IH Day to raise awareness, educate and uplift the voices of the IH community across the globe.   Visit the Hypersomnia Foundation website to learn more: bit.ly/3K3R9tu #ThisIsIH

Centessa is a proud sponsor of the @Hypersomnia Foundation’s #BeyondSleepy 2024 Conference. #BeyondSleepy seeks to provide information on research and treatments to individuals with idiopathic hypersomnia (IH), narcolepsy and other sleep-wake disorders. Our team is on the ground in Houston for this important event!

https://lnkd.in/egm8D9cG

Today we announced financial results and business highlights for Q1 2024. Read the full press release for more details: https://lnkd.in/eyTgne4X